# FDA recall D-0412-2022

> **Edge Pharma, LLC** · Class II · drug recall initiated 2021-12-06.

## Product

MVASI, (bevacizumab-awwb), Sterile Ophthalmic Solution for Injection, 3.25mg/0.13mL (25 mg/mL) 0.13 mL per syringe, Dose: 1.25mg/0.05mL, Single Use Syringe For Intraocular Injection, Edge Pharma, LLC, 856 Hercules Dr. Colchester, VT 05446,  NDC 05446-1661-13

## Reason for recall

Lack of Assurance of Sterility

## Distribution

nationwide

## Key facts

- **Recall number:** D-0412-2022
- **Recalling firm:** Edge Pharma, LLC
- **Classification:** Class II
- **Product type:** drug
- **Status:** Terminated
- **Initiation date:** 2021-12-06
- **Report date:** 2022-02-02
- **Termination date:** 2023-06-07

- **Voluntary/Mandated:** Voluntary: Firm initiated
- **Location:** Colchester, VT, United States

## Primary source

FDA Enforcement Reports: https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0412-2022

## Citation

> AI Analytics. FDA recall D-0412-2022. Retrieved 2026-06-02 from https://api.ai-analytics.org/recall/D-0412-2022. Source: US FDA. Licensed CC0.

---

*[Dataset catalog](/datasets/) · [FDA recalls dataset](/datasets/fda-recalls) · CC0 1.0*